BACKGROUND: Na(V)1.5 is a mechanosensitive voltage-gated sodium-selective ion channel responsible for the depolarizing current and maintenance of the action potential plateau in the heart. Ranolazine is a Na(V)1.5 antagonist with antianginal and antiarrhythmic properties. METHODS AND RESULTS: Mechanosensitivity of Na(V)1.5 was tested in voltage-clamped whole cells and cell-attached patches by bath flow and patch pressure, respectively. In whole cells, bath flow increased peak inward current in both murine ventricular cardiac myocytes (24±8%) and human embryonic kidney 293 cells heterologously expressing Na(V)1.5 (18±3%). The flow-induced increases in peak current were blocked by ranolazine. In cell-attached patches from cardiac myocytes and Na(V)1.5-expressing human embryonic kidney 293 cells, negative pressure increased Na(V) peak currents by 27±18% and 18±4% and hyperpolarized voltage dependence of activation by -11 mV and -10 mV, respectively. In human embryonic kidney 293 cells, negative pressure also increased the window current (250%) and increased late open channel events (250%). Ranolazine decreased pressure-induced shift in the voltage dependence (IC(50) 54 μmol/L) and eliminated the pressure-induced increases in window current and late current event numbers. Block of Na(V)1.5 mechanosensitivity by ranolazine was not due to the known binding site on DIVS6 (F1760). The effect of ranolazine on mechanosensitivity of Na(V)1.5 was approximated by lidocaine. However, ionized ranolazine and charged lidocaine analog (QX-314) failed to block mechanosensitivity. CONCLUSIONS: Ranolazine effectively inhibits mechanosensitivity of Na(V)1.5. The block of Na(V)1.5 mechanosensitivity by ranolazine does not utilize the established binding site and may require bilayer partitioning. Ranolazine block of Na(V)1.5 mechanosensitivity may be relevant in disorders of mechanoelectric dysfunction.
BACKGROUND:Na(V)1.5 is a mechanosensitive voltage-gated sodium-selective ion channel responsible for the depolarizing current and maintenance of the action potential plateau in the heart. Ranolazine is a Na(V)1.5 antagonist with antianginal and antiarrhythmic properties. METHODS AND RESULTS: Mechanosensitivity of Na(V)1.5 was tested in voltage-clamped whole cells and cell-attached patches by bath flow and patch pressure, respectively. In whole cells, bath flow increased peak inward current in both murineventricular cardiac myocytes (24±8%) and humanembryonic kidney 293 cells heterologously expressing Na(V)1.5 (18±3%). The flow-induced increases in peak current were blocked by ranolazine. In cell-attached patches from cardiac myocytes and Na(V)1.5-expressing humanembryonic kidney 293 cells, negative pressure increased Na(V) peak currents by 27±18% and 18±4% and hyperpolarized voltage dependence of activation by -11 mV and -10 mV, respectively. In humanembryonic kidney 293 cells, negative pressure also increased the window current (250%) and increased late open channel events (250%). Ranolazine decreased pressure-induced shift in the voltage dependence (IC(50) 54 μmol/L) and eliminated the pressure-induced increases in window current and late current event numbers. Block of Na(V)1.5 mechanosensitivity by ranolazine was not due to the known binding site on DIVS6 (F1760). The effect of ranolazine on mechanosensitivity of Na(V)1.5 was approximated by lidocaine. However, ionizedranolazine and charged lidocaine analog (QX-314) failed to block mechanosensitivity. CONCLUSIONS:Ranolazine effectively inhibits mechanosensitivity of Na(V)1.5. The block of Na(V)1.5 mechanosensitivity by ranolazine does not utilize the established binding site and may require bilayer partitioning. Ranolazine block of Na(V)1.5 mechanosensitivity may be relevant in disorders of mechanoelectric dysfunction.
Authors: Matteo Vatta; Michael J Ackerman; Bin Ye; Jonathan C Makielski; Enoh E Ughanze; Erica W Taylor; David J Tester; Ravi C Balijepalli; Jason D Foell; Zhaohui Li; Timothy J Kamp; Jeffrey A Towbin Journal: Circulation Date: 2006-10-23 Impact factor: 29.690
Authors: Bidisha Sinha; Darius Köster; Richard Ruez; Pauline Gonnord; Michele Bastiani; Daniel Abankwa; Radu V Stan; Gillian Butler-Browne; Benoit Vedie; Ludger Johannes; Nobuhiro Morone; Robert G Parton; Graça Raposo; Pierre Sens; Christophe Lamaze; Pierre Nassoy Journal: Cell Date: 2011-02-04 Impact factor: 41.582
Authors: Jens A Lundbaek; Pia Birn; Anker J Hansen; Rikke Søgaard; Claus Nielsen; Jeffrey Girshman; Michael J Bruno; Sonya E Tape; Jan Egebjerg; Denise V Greathouse; Gwendolyn L Mattice; Roger E Koeppe; Olaf S Andersen Journal: J Gen Physiol Date: 2004-05 Impact factor: 4.086
Authors: Umberto Banderali; Peter F Juranka; Robert B Clark; Wayne R Giles; Catherine E Morris Journal: Channels (Austin) Date: 2010-01-06 Impact factor: 2.581
Authors: Peter J Mohler; Ilaria Rivolta; Carlo Napolitano; Guy LeMaillet; Stephen Lambert; Silvia G Priori; Vann Bennett Journal: Proc Natl Acad Sci U S A Date: 2004-12-03 Impact factor: 11.205
Authors: Leila Neshatian; Peter R Strege; Poong-Lyul Rhee; Robert E Kraichely; Amelia Mazzone; Cheryl E Bernard; Robert R Cima; David W Larson; Eric J Dozois; Crystal F Kline; Peter J Mohler; Arthur Beyder; Gianrico Farrugia Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-07-16 Impact factor: 4.052